These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1158313)

  • 1. L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
    Ohmoto T; Kishikawa H
    Folia Psychiatr Neurol Jpn; 1975; 29(1):1-12. PubMed ID: 1158313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
    Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
    J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of parkinsonism with l-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study.
    Dietrichson P; Presthus J; Holmsen R
    Eur Neurol; 1975; 13(4):339-49. PubMed ID: 1149754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
    Lieberman A; Goodgold A; Jonas S; Leibowitz M
    Neurology; 1975 Oct; 25(10):911-6. PubMed ID: 1101099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 10. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
    Ludin HP; Bass-Verrey F
    J Neural Transm; 1976; 38(3-4):249-58. PubMed ID: 956811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
    Dowzenko A; Buksowicz C; Kuran W
    Neurol Neurochir Pol; 1975; 9(4):487-93. PubMed ID: 1165836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
    Omoto T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biochemical evaluation of the effectiveness of antiparkinson preparations containing L-DOPA].
    Vartanian KZ
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(12):1777-81. PubMed ID: 6803476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.
    Kartzinel R; TEYCHENNE P; Gillespie MM; Perlow M; Gielen AC; Sadowsky DA; Calne DB
    Lancet; 1976 Aug; 2(7980):272-5. PubMed ID: 59850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.
    Bermejo Pareja F; Martinez-Martin P; Muradas V; de Yébenes JG
    Acta Neurol Scand; 1985 Nov; 72(5):506-11. PubMed ID: 4082917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease.
    Ogasahara S; Nishikawa Y; Takahashi M; Wada K; Nakamura Y; Yorifuji S; Tarui S
    J Neurol Sci; 1984; 66(2-3):151-63. PubMed ID: 6530609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
    Namba S; Omoto T; Kishikawa H
    No To Shinkei; 1976 Aug; 28(8):815-22. PubMed ID: 829033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.